Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact

Halozyme Therapeutics Inc (NASDAQ:HALO) has announced a collaboration and license agreement with Chugai Pharmaceutical Co Ltd for exclusive access to Halozyme's ENHANZE drug delivery technology for an undisclosed target. 

  • The ENHANZE drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). 
  • rHuPH20 has been shown to remove traditional limitations on the volume of biologics delivered subcutaneously. 
  • Using rHuPH20, some biologics and compounds administered intravenously may instead be delivered subcutaneously. 
  • ENHANZE may also benefit subcutaneous biologics by reducing the need for multiple injections. 
  • Related: Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder.
  • Under the agreement terms, Chugai will make an upfront payment of $25 million to Halozyme and is obligated to make potential future milestone payments of up to $160 million. 
  • Halozyme will also receive royalties on sales of commercialized medicines using the ENHANZE® technology.
  • Chugai represents Halozyme's twelfth global collaboration and license partner for the ENHANZE technology, covering more than 60 therapeutic targets, including five commercialized products.
  • Price Action: HALO shares are up 0.75% at $37.86 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.